peritoneal	dialysis	266	458	557	1.2253
vascular	access	149	250	179	1.7295
renal	failure	148	521	162	1.4511
renal	function	113	521	167	1.3207
renal	disease	79	521	123	1.2980
renal	replacement	69	521	85	1.3997
peritoneal	cavity	42	458	48	1.4883
most	patients	42	98	277	1.3967
molecular	weight	41	70	106	1.9495
normal	range	40	149	56	1.8878
human	erythropoietin	39	90	45	2.1908
total	calcium	37	149	77	1.7157
solute	removal	37	182	103	1.5024
solute	clearance	37	182	101	1.5110
present	study	37	56	103	2.0143
peritoneal	membrane	37	458	112	1.0653
dry	weight	37	41	106	2.1373
extracorporeal	circuit	35	80	49	2.1579
fluid	removal	34	196	103	1.4335
fluid	overload	33	196	37	1.8652
arteriovenous	fistula	33	55	42	2.3621
whole	blood	32	40	282	1.6600
significant	difference	29	199	42	1.7474
general	population	29	51	45	2.3088
bacterial	growth	29	69	48	2.1495
solute	concentration	28	182	64	1.5881
chronic	dialysis	28	95	557	0.9307
catabolic	rate	28	40	58	2.2888
white	blood	27	32	282	1.6831
mononuclear	cells	26	27	69	2.3519
folic	acid	26	26	85	2.2777
solute	transport	25	182	66	1.5255
extracorporeal	blood	25	80	282	1.2518
oxidative	burst	24	38	24	2.6274
uraemic	patients	23	62	277	1.3340
adequate	dialysis	23	80	557	0.9199
key	words	21	30	27	2.6209
dialytic	dose	21	47	66	2.0377
dialysate	sodium	21	181	35	1.7276
total	protein	20	149	94	1.3619
significant	increase	20	199	74	1.3401
dialysate	flow	20	181	49	1.5603
other	hand	19	212	23	1.7978
uremic	patients	18	77	277	1.1335
synthetic	membranes	18	32	95	1.9795
significant	differences	18	199	44	1.5201
nutritional	status	18	50	41	2.1507
fluid	balance	18	196	25	1.7722
anastomotic	site	18	25	30	2.5874
statistical	analysis	17	42	51	2.1068
ptfe	grafts	17	21	36	2.5591
linear	regression	17	30	28	2.5133
intradialytic	hypotension	17	55	32	2.1921
hollow	fiber	17	22	17	2.8647
cardiac	output	17	73	20	2.2732
uric	acid	16	16	85	2.2777
metabolic	acidosis	16	53	40	2.0849
kinetic	modeling	16	24	19	2.7523
dietary	protein	16	58	94	1.6747
cellulosic	membranes	16	24	95	2.0533
venous	stenosis	15	130	25	1.8714
several	studies	15	86	133	1.3249
renal	osteodystrophy	15	521	15	1.4903
recent	years	15	77	39	1.9057
recent	studies	15	77	133	1.3729
peritoneal	equilibration	15	458	16	1.5183
mean	age	15	85	29	1.9914
many	patients	15	73	277	1.0774
fluid	intake	15	196	43	1.4575
chronic	haemodialysis	15	95	48	1.7243
arterial	blood	15	107	282	0.9036
active	iron	15	39	90	1.8379
same	time	14	90	51	1.6915
ascorbic	acid	14	14	85	2.2777
silent	ischemia	13	13	24	2.8269
peritoneal	function	13	458	167	0.4375
oral	iron	13	56	90	1.6187
net	ultrafiltration	13	33	67	1.9765
individual	patient	13	52	49	1.9149
autogenous	oxygenation	13	13	15	3.0311
subclavian	vein	12	15	55	2.3699
secondary	hyperparathyroidism	12	28	14	2.6930
reverse	osmosis	12	15	15	2.9341
osmotic	agent	12	36	22	2.3876
inadequate	dialysis	12	30	557	1.0634
immune	response	12	32	55	2.0408
high	risk	12	146	80	1.2189
cardiopulmonary	recirculation	12	18	14	2.8849
arterial	line	12	107	21	1.9347
vascular	grafts	11	250	36	1.2943
vascular	disease	11	250	123	0.7607
such	patients	11	71	277	0.9548
social	worker	11	27	11	2.7758
significant	decrease	11	199	35	1.4056
renal	clearance	11	521	101	0.5274
parenteral	iron	11	24	90	1.9141
normal	bone	11	149	66	1.2558
molecular	weights	11	70	11	2.3621
low	serum	11	93	49	1.5899
important	factor	11	88	33	1.7855
immunocompetent	cells	11	11	69	2.3683
diabetic	patients	11	20	277	1.5050
convective	transport	11	25	66	2.0311
arteriovenous	fistulas	11	55	13	2.3942
anaphylactoid	reactions	11	11	46	2.5444
alkaline	phosphatase	11	11	11	3.1658
advanced	glycation	11	20	12	2.8683
widespread	use	10	15	91	2.0720
wide	range	10	21	56	2.1367
small	solutes	10	91	25	1.8502
significant	changes	10	199	44	1.2648
other	factors	10	212	67	1.0547
long	term	10	35	17	2.4326
human	blood	10	90	282	0.8027
effective	surface	10	34	43	2.0422
coronary	artery	10	25	46	2.1465
clinical	use	10	248	91	0.8537
clinical	studies	10	248	133	0.6888
clinical	practice	10	248	17	1.5822
clinical	outcome	10	248	40	1.2106
arterial	needle	10	107	20	1.8767
adynamic	bone	10	16	66	2.1835
venous	blood	9	130	282	0.5972
vascular	graft	9	250	25	1.3655
uremic	toxins	9	77	19	1.9961
total	body	9	149	36	1.4319
solute	flux	9	182	16	1.6972
significant	decline	9	199	13	1.7486
significant	correlation	9	199	25	1.4646
renal	transplantation	9	521	11	1.4032
renal	insufficiency	9	521	11	1.4032
recent	study	9	77	103	1.2621
radial	artery	9	9	46	2.5444
prospective	study	9	30	103	1.6714
prospective	studies	9	30	133	1.5604
preventive	measures	9	12	41	2.4694
patient	outcome	9	81	40	1.6508
partial	thromboplastin	9	17	9	2.9767
other	authors	9	212	14	1.6889
oncotic	pressure	9	9	69	2.3683
neutrophil	function	9	24	167	1.5585
lean	body	9	9	36	2.6508
intraperitoneal	volume	9	38	71	1.7304
inner	surface	9	12	43	2.4487
immune	complexes	9	32	9	2.7020
hyperparathyroid	bone	9	9	66	2.3876
higher	levels	9	66	45	1.6886
healthy	volunteers	9	39	11	2.5289
extracorporeal	circulation	9	80	27	1.8269
ceramic	membranes	9	10	95	2.1837
biocompatible	membrane	9	26	112	1.6972
adverse	effects	9	18	59	2.1353
active	oxygen	9	39	31	2.0790
abdominal	wall	9	39	21	2.2481
abdominal	pain	9	39	16	2.3662
ventricular	hypertrophy	8	42	8	2.5839
uraemic	toxins	8	62	19	2.0391
uraemic	state	8	62	50	1.6189
upper	limit	8	22	15	2.5917
systemic	acidosis	8	36	40	1.9519
symptomatic	hypotension	8	11	32	2.5637
statistical	significance	8	42	11	2.4456
solute	mass	8	182	24	1.4700
solute	concentrations	8	182	41	1.2374
renal	bone	8	521	66	0.5739
red	blood	8	19	282	1.3812
proinflammatory	cytokines	8	10	12	3.0311
pet	data	8	10	78	2.2181
parathyroid	hormone	8	22	9	2.8136
normal	serum	8	149	49	1.2469
normal	ranges	8	149	8	2.0340
neutrophil	oxygen	8	24	31	2.2387
most	cases	8	98	29	1.6566
lumbar	spine	8	8	9	3.2529
intravenous	administration	8	27	26	2.2639
informed	consent	8	9	9	3.2018
increased	risk	8	105	80	1.1860
hydraulic	permeability	8	10	26	2.6953
high	mortality	8	146	29	1.4835
hemodialyzed	patients	8	8	277	1.7647
healthy	subjects	8	39	16	2.3151
fungal	peritonitis	8	13	31	2.5049
european	countries	8	20	26	2.3942
endocrine	alterations	8	21	16	2.5839
controlled	trials	8	23	18	2.4932
contaminated	dialysate	8	11	59	2.2980
clinical	symptoms	8	248	36	1.1595
chronic	hemodialysis	8	95	44	1.4891
cephalic	vein	8	9	55	2.4156
cardiac	arrhythmias	8	73	22	1.9045
autologous	fistulae	8	10	14	2.9641
artificial	membrane	8	26	112	1.6460
acute	reactions	8	60	46	1.6693
venous	side	7	130	31	1.4469
vast	majority	7	8	9	3.1949
vascular	response	7	250	55	0.9139
vascular	resistance	7	250	27	1.2229
uremic	plasma	7	77	57	1.4099
untreated	cellulose	7	10	24	2.6720
thrombotic	tendency	7	12	13	2.8591
stable	patients	7	34	277	1.0783
semipermeable	membrane	7	8	112	2.0999
red	cells	7	19	69	1.9346
radical	production	7	8	17	2.9187
pulmonary	artery	7	49	46	1.6993
previous	study	7	47	103	1.3673
previous	reports	7	47	18	2.1249
present	case	7	56	13	2.1901
permeable	membranes	7	12	95	1.9953
peripheral	vein	7	29	55	1.8495
patient	clearance	7	81	101	1.1394
parenteral	nutrition	7	24	17	2.4416
osmotic	agents	7	36	21	2.1737
nutritional	state	7	50	50	1.6543
normal	values	7	149	41	1.2663
normal	plasma	7	149	57	1.1232
most	dialysis	7	98	557	0.3152
mesothelial	cells	7	11	69	2.1720
many	years	7	73	39	1.5979
many	studies	7	73	133	1.0651
malnourished	patients	7	15	277	1.4337
last	decade	7	22	13	2.5959
intradialytic	period	7	55	31	1.8205
interdialytic	weight	7	24	106	1.6467
intensive	care	7	19	37	2.2053
independent	risk	7	12	80	2.0700
hypotensive	episodes	7	11	33	2.4923
high	rate	7	146	58	1.1245
high	doses	7	146	31	1.3965
gold	standard	7	7	13	3.0932
glomerular	filtration	7	8	13	3.0352
further	studies	7	54	133	1.1960
fluid	volume	7	196	71	0.9087
fluid	loss	7	196	24	1.3798
femoral	vein	7	21	55	1.9897
external	shunt	7	23	9	2.7363
endocrine	organs	7	21	10	2.7300
different	membrane	7	122	112	0.9167
dietary	intake	7	58	43	1.6554
dialysate	compartment	7	181	17	1.5641
dialysate	calcium	7	181	77	0.9081
dialysate	bicarbonate	7	181	33	1.2761
controlled	trial	7	23	16	2.4864
comorbid	conditions	7	10	34	2.5208
common	cause	7	39	37	1.8930
clinical	consequences	7	248	16	1.4537
clinical	assessment	7	248	23	1.2961
cardiovascular	disease	7	33	123	1.4438
biocompatible	membranes	7	26	95	1.6596
bacterial	contamination	7	69	18	1.9581
adequate	blood	7	80	282	0.6989
volumetric	control	6	17	40	2.1528
venous	segment	6	130	12	1.7922
venous	return	6	130	9	1.9171
venous	pressure	6	130	69	1.0325
venous	needle	6	130	20	1.5703
venous	dialysis	6	130	557	0.1255
venous	catheters	6	130	25	1.4734
various	dialysis	6	76	557	0.3586
unselected	patients	6	6	277	1.7647
total	clearance	6	149	101	0.8078
surgical	repair	6	41	6	2.5944
supine	position	6	6	13	3.0932
small	number	6	91	27	1.5949
significant	increases	6	199	14	1.5403
significant	change	6	199	13	1.5725
short	time	6	31	51	1.7864
routine	use	6	25	91	1.6283
repeated	episodes	6	24	33	2.0866
renal	urea	6	521	30	0.7913
regular	use	6	26	91	1.6113
regular	dialysis	6	26	557	0.8245
prolonged	bleeding	6	30	39	1.9171
previous	studies	6	47	133	1.1894
polyacrylonitrile	membrane	6	7	112	2.0910
peritoneal	catheter	6	458	32	0.8193
peripheral	blood	6	29	282	1.0727
patient	selection	6	81	12	1.9976
palliative	medicine	6	11	7	3.0988
other	words	6	212	27	1.2276
osmotic	gradient	6	36	6	2.6508
oral	postdialysis	6	56	13	2.1232
numerous	studies	6	14	133	1.7153
negative	pressure	6	30	69	1.6693
nasal	carriage	6	11	6	3.1658
myocardial	ischemia	6	28	24	2.1579
myocardial	infarction	6	28	10	2.5381
multivariate	analysis	6	7	51	2.4326
morbid	events	6	9	35	2.4870
mean	duration	6	85	21	1.7337
many	factors	6	73	67	1.2959
many	dialysis	6	73	557	0.3761
low	blood	6	93	282	0.5666
logistic	regression	6	8	28	2.6351
linear	relationship	6	30	26	2.0932
left	atrium	6	13	9	2.9171
large	volumes	6	70	12	2.0610
isotonic	saline	6	7	21	2.8180
intradialytic	arrhythmias	6	55	22	1.9025
intraclass	correlation	6	6	25	2.8092
individual	patients	6	52	277	0.8268
increased	incidence	6	105	28	1.5170
important	role	6	88	31	1.5495
important	factors	6	88	67	1.2147
immune	status	6	32	41	1.8674
hydrostatic	pressure	6	9	69	2.1922
high	incidence	6	146	28	1.3738
high	concentrations	6	146	41	1.2082
high	blood	6	146	282	0.3707
gastrointestinal	bleeding	6	9	39	2.4400
functional	iron	6	29	90	1.5687
first	time	6	83	51	1.3587
final	concentration	6	28	64	1.7320
european	dialysis	6	20	557	0.9384
elderly	patients	6	8	277	1.6397
early	years	6	54	39	1.6618
diffusive	transport	6	23	66	1.8040
different	results	6	122	72	1.0416
different	methods	6	122	31	1.4076
different	dialysis	6	122	557	0.1531
coronary	blood	6	25	282	1.1371
conventional	pfd	6	38	6	2.6274
congestive	heart	6	6	24	2.8269
conflicting	results	6	7	72	2.2829
clinical	signs	6	248	11	1.5495
clinical	relevance	6	248	10	1.5908
clinical	condition	6	248	17	1.3604
calculated	transferrin	6	11	31	2.4525
beneficial	effect	6	11	59	2.1731
alternative	pathway	6	25	14	2.4412
abstract	background	6	8	11	3.0408
weekly	creatinine	5	17	15	2.4996
ventricular	ectopy	5	42	10	2.2829
venous	line	5	130	21	1.4700
unrestricted	pore	5	6	11	3.0866
total	volume	5	149	71	0.8817
total	homocysteine	5	149	5	2.0340
total	buffer	5	149	18	1.4777
theoretical	description	5	17	12	2.5965
surgical	intervention	5	41	18	2.0381
supraventricular	arrhythmias	5	13	22	2.4498
sudden	death	5	12	21	2.5047
subcutaneous	tunnel	5	18	6	2.8727
solute	transfer	5	182	16	1.4419
similar	results	5	44	72	1.4053
short	dialysis	5	31	557	0.6689
several	patients	5	86	277	0.5291
several	factors	5	86	67	1.1455
selected	patients	5	7	277	1.6185
retrospective	studies	5	17	133	1.5518
repeated	puncture	5	24	14	2.3798
renal	diseases	5	521	24	0.8091
recombinant	erythropoietin	5	8	45	2.3498
reactive	oxygen	5	8	31	2.5117
pulmonary	vasculature	5	49	6	2.4378
pulmonary	circulation	5	49	27	1.7846
polycystic	kidney	5	6	15	2.9519
peritoneal	transport	5	458	66	0.4257
peritoneal	permeability	5	458	26	0.8303
peritoneal	exchange	5	458	19	0.9665
patient	population	5	81	45	1.3444
palliative	care	5	11	37	2.2965
other	groups	5	212	23	1.2181
other	complications	5	212	69	0.7409
normotensive	patients	5	6	277	1.6855
normal	saline	5	149	21	1.4107
nitric	oxide	5	5	6	3.4290
new	techniques	5	79	25	1.6106
net	protein	5	33	94	1.4145
negative	nitrogen	5	30	9	2.4748
most	studies	5	98	133	0.7910
medical	management	5	51	15	2.0225
mass	transport	5	19	66	1.8078
male	patients	5	7	277	1.6185
main	factors	5	53	67	1.3558
lower	limit	5	58	15	1.9666
lower	levels	5	58	45	1.4895
longer	dialysis	5	18	557	0.9050
long	dialysis	5	35	557	0.6162
larger	solutes	5	27	25	2.0768
large	amounts	5	70	20	1.7600
isolated	ultrafiltration	5	12	67	2.0009
ischemic	heart	5	12	24	2.4467
intestinal	absorption	5	12	21	2.5047
infective	complications	5	8	69	2.1642
increased	protein	5	105	94	0.9118
immediate	postdialysis	5	20	13	2.4911
ill	patients	5	6	277	1.6855
higher	incidence	5	66	28	1.6394
high	cost	5	146	15	1.5657
greatest	frequency	5	10	11	2.8647
greater	risk	5	90	80	1.0488
general	agreement	5	51	10	2.1985
fluid	accumulation	5	196	12	1.5347
first	year	5	83	9	2.0328
first	round	5	83	8	2.0840
first	hour	5	83	13	1.8731
few	patients	5	40	277	0.8616
endothelial	dysfunction	5	23	15	2.3683
different	dialysates	5	122	6	2.0416
dialysate	temperature	5	181	10	1.6484
dialysate	solution	5	181	23	1.2867
dialysate	samples	5	181	12	1.5693
dialysate	protein	5	181	94	0.6753
dialysate	composition	5	181	15	1.4723
cumulative	incidence	5	12	28	2.3798
cooperative	dialysis	5	6	557	1.3821
conventional	haemodialysis	5	38	48	1.6451
conventional	ecc	5	38	5	2.6274
conventional	dialysis	5	38	557	0.5805
comparative	studies	5	15	133	1.6062
closed	loop	5	16	6	2.9238
clinical	parameters	5	248	40	0.9096
clinical	impact	5	248	16	1.3075
clinical	hemodialysis	5	248	44	0.8682
cardiac	failure	5	73	162	0.8333
brachial	artery	5	7	46	2.3983
better	survival	5	38	34	1.7949
bacterial	count	5	69	7	2.2222
arterial	pressure	5	107	69	1.0379
antiglomerular	basement	5	5	6	3.4290
aneurysmal	dilatation	5	6	12	3.0488
amyloid	deposits	5	12	7	2.9818
allergic	reactions	5	10	46	2.2434
adequate	nutrition	5	80	17	1.7726
acute	complications	5	60	69	1.2891
abdominal	cavity	5	39	48	1.6338